TEL AVIV, ISRAEL – October 17, 2006 – Compugen Ltd. (NASDAQ: CGEN) announced today that Alon Amit, Ph.D., Vice President Science and Technology, Compugen USA Inc., is scheduled to present at the upcoming BIO InvestorForum at 12:00 PM (Pacific Time), on Thursday, October 19, 2006 at the Palace Hotel in San Francisco.
A live Webcast of the presentation will be available at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=CGEN&item_id=1400391 and on Compugen’s Website. A replay will be available one hour after the presentation.
Compugen’s mission is to be the world leader in the discovery and licensing of product candidates to the drug and diagnostic industry. The Company’s powerful discovery engines enable the predictive discovery of numerous potential therapeutics and diagnostic biomarkers. This capability results from the Company’s decade-long pioneering efforts in the deeper understanding of important biological phenomena at the molecular level through the incorporation of ideas and methods from mathematics, computer science and physics into biology, chemistry and medicine. To date, Compugen’s product discovery efforts and its initial discovery engines have focused mainly within the areas of cancer, immune-related and cardiovascular diseases. The Company’s primary commercialization pathway for its therapeutic and diagnostic product candidates is to enter into milestone and revenue sharing out-licensing and joint development agreements with leading companies. Compugen has established an agricultural biotechnology affiliate – Evogene, and a small-molecule drug discovery affiliate – Keddem Bioscience. For additional information, please visit Compugen’s corporate Website at www.cgen.com.